Efficacy of sarolaner, a novel oral isoxazoline, against two common mite infestations in dogs: Demodex spp. and Otodectes cynotis

Abstract

The efficacy of sarolaner (Simparica™, Zoetis) was evaluated against Demodex spp. in dogs with generalized demodicosis and against Otodectes cynotis (otodectic mange) in dogs with induced infestations. In the first study, 16 dogs with clinical signs of generalized demodicosis and positive for Demodex spp. mites were randomly assigned to treatment with either sarolaner (2mg/kg) orally on Days 0, 30 and 60, or topical imidacloprid (10mg/kg) plus moxidectin (2.5mg/kg) solution every 7 days from Day 0 to Day 81. For sarolaner-treated dogs, pretreatment mite counts were reduced by 97.1% at 14days and 99.8% by 29 days after the first dose, with no live mites detected thereafter. Weekly imidacloprid plus moxidectin resulted in 84.4 and 95.6% reduction at these two time points, respectively, with no mites detected from Day 74 on. All dogs in both groups showed marked improvement in the clinical signs of demodicosis. In the second study, 32 dogs with induced infestations of O. cynotis were randomly assigned (eight per group) to oral sarolaner (2mg/kg) as a single treatment on Day 0 or as a two dose regime (Days 0 and 30), or a placebo group for each of the dose regimes. Sarolaner administered at 2mg/kg as a single oral dose resulted in a 98.2% reduction at Day 30 and two doses of sarolaner, administered one month apart, resulted in a 99.5% reduction in ear mites at Day 60 compared to placebo controls. There were no treatment related adverse events in either study. In these studies, sarolaner at an oral dose of 2mg/kg was highly effective in reducing the live mite counts associated with a natural infestation of Demodex spp. and an induced infestation of O. cynotis. In addition, the Demodex-infested dogs showed a marked improvement in the clinical signs of generalized demodicosis.

Canine demodicosis: a retrospective study of a veterinary hospital population in California,USA(2000–2016)

“…The advent of the isoxazoline group of flea and tick products, including fluralaner, afoxolaner and sarolaner, has been accompanied by reports of acaricidal activity against D . canis . Anecdotally, since 2015 the vast majority of dogs with demodicosis presenting to the teaching hospital were prescribed an isoxazoline medication.…”

The use of oral fluralaner for the treatment of feline generalised demodicosis: a case report

“…, Six et al . ). Recently, the pharmacokinetic of fluralaner has been shown to be comparable in dogs and cats after topical and intravenous administration and a novel spot‐on formulation for cats will soon be available for treatment against fleas and ticks (Kilp et al .…”

Uso do fluralaner no tratamento da demodicidose canina juvenil generalizada: relato de caso

“…Isso é extremamente vantajoso em relação às lactonas macrocíclicas, que demandam administrações que podem ter frequência diária e por longos períodos para se alcançar a cura parasitológica do animal, e também no que se refere ao uso do amitraz, que requer banhos semanais (Mueller, 2004;Delayte, 2006). Outras moléculas do grupo das isoxazolinas, como o sarolaner e o afoxolaner, também exibiram boa eficácia contra o D. canis, o que levou a reduções na quantidade do ácaro de 99,8% e 99,2%, respectivamente, em um mês após a administração (Beugnet et al, 2016;Six et al, 2016). Para ambos os casos relatados, a domperidona foi utilizada com a finalidade imunoestimulante.…”